Тайленол Drug photo

The description is actual on 28.06.2016

  • Latin name: Tylenol
  • ATH code: N02BE01
  • Active ingredient: Paracetamol
  • Producer: Johnson and Johnson (USA), McNail (USA), Silag (Switzerland)


In 1 kapleta there is active agent a paracetamol of 500 mg.

Release form


Pharmacological action

Non-narcotic, analgetic means.

Pharmacodynamics and pharmacokinetics

Active component is paracetamol. The main substance makes impact on the centers of thermal control, pain, blocks cyclooxygenase-1,2 in the central nervous system.

Cellular peroxidases exert neutralized impact on active agent of drug in the inflammatory centers that completely blocks antiinflammatory influence.

Medicine does not exert negative impact on a mucous wall of a digestive tract, on a water salt metabolism, does not cause a delay of water and ions of sodium.

Indications to use

Taylenol appoint at a pain syndrome of weak and moderate character: neuralgia, headache, arthralgia, algodismenoreya, mialgiya, dentagra, migraine.

Drug is shown at the feverish syndrome accompanied infectious diseases.


Taylenol do not appoint at intolerance of paracetamol, in the period of a neonatality before achievement of monthly age.

At a viral hepatitis, pregnancy, advanced age, feeding by a breast, alcoholic damages of a liver, a diabetes mellitus, deficit glyukozo-6-fosfatdegidrogenazy, at high-quality hyperbilirubinemias, a liver failure, pathology of kidneys, Gilbert's syndrome paracetamol is appointed with care.

Side effects

Integuments: Quincke's disease, rash, skin itch, Lyell's disease (epidermal, toxic necrolysis), Stephens-Johnson's syndrome, exudative multiformny erythema.

The central nervous system (at reception of the raised paracetamol doses): orientation disturbance, psychomotor excitement, dizzinesses.

Alimentary system: pains in epigastriums, nausea, increase of level of enzymes of a liver, gepatonekroz.

Endocrine system: hypoglycemic coma, hypoglycemia.

Bodies of a hemopoiesis: methemoglobinemia (heartaches, short wind, cyanosis), sulfhemoglobinemia, anemia. Reception of high doses can cause development of thrombocytopenia, a leukopenia, aplastic anemia, an agranulocytosis, pancytopenia.

Urinary system: a papillary necrosis, nephrotoxicity in the form of intersticial nephrite, renal colic.

Taylenol, application instruction (Way and dosage)

Pill Taylenol is taken inside, washing down with enough water, it is desirable in 2 hours after food.

The one-time dosage for adults makes 500 mg, maximum – 1 gram.

Medicine is appointed to 4 times a day. Duration of therapy is 5-7 days.

At Gilbert's syndrome, pathology of hepatic, renal systems it is recommended to increase an interval between medicine receptions, or to reduce a dosage.


The clinical picture of acute overdose is developed in 6-14 hours after medicine reception Taylenol.

The symptomatology of chronic overdose is registered in 2-4 weeks.

The increased sweating, disturbances in work of a digestive tract is noted (discomfort in epigastriums, abdominal pains, diarrhea, nausea, vomiting, appetite disturbances).

At chronic overdose the adynamia, weakness, the increased sweating, gepatonekroz, hepatotoxic effect which can be complicated by hepatic encephalopathy is noted: stupor, oppression of the central nervous system, disturbance of thinking.

The metabolic acidosis, spasms, a coma, hypocoagulation, wet brain, respiratory depression, development of the IDCS, arrhythmia, a hypoglycemia is registered.

Introduction of predecessors of synthesis of glutathione, donators of SH groups is recommended.


Taylenol is capable to reduce efficiency of uricosuric medicines.

Medicine strengthens effect of anticoagulating drugs as a result of decrease in process of synthesizing of procoagulant factors in hepatic system.

At a concomitant use of barbiturates, ethanol, Phenytoinum, phenylbutazone, rifampicin, tricyclic antidepressants, phenylbutazone, inductors of a microsomal oxidation, hepatotoxic means development of active hydroxylated metabolites raises that considerably increases risk of development of severe forms of intoxications even at insignificant overdoses.

Efficiency of paracetamol decreases at long reception of barbiturates.

At reception of ethanol the risk of development of an acute form of pancreatitis increases.

The risk of hepatotoxic damage decreases at reception of Cimetidinum, inhibitors of a microsomal oxidation.

Long therapy by Taylenol and other drugs from NPVS group increases risk of development of a papillary renal necrosis, "analgetic" nephropathy, and also accelerates approach of an end-stage of a renal failure.

Prolonged and simultaneous treatment by salicylates and paracetamol leads to development of oncological pathology from a bladder, renal system.

Medicine Diflunisal doubles the level of plasma concentration of active agent of Taylenol that increases risk of development of a hepatotoxic by 50%.

The Gematotoksichnost of a medicine increases at use of myelotoxic means.

Terms of sale

According to the recipe.

Storage conditions

In the place, unavailable to children, at a temperature of 15-30 degrees Celsius.

Period of validity

4 years.

Special instructions

At patients with an alcoholic hepatosis the risk of damage of tissues of liver during therapy by paracetamol considerably increases.

At a long feverish syndrome (more than 3 days) against treatment by drug Taylenol it is necessary to address for consultation the specialist.

The medicine can distort results of laboratory researches, influence the level of uric acid, glucose.

Therapy by Taylenol demands control over work of hepatic system, a condition of blood.

With a diabetes mellitus it is important to patients to consider the content of sucrose in syrup (in 5 ml – 0,06XE).

Taylenol's analogs

Analogs are drugs: Apap, Panadolum, Paracetamol, Efferalgan and other anesthetics on the basis of paracetamol.

Section: For joints Anesthetics
in more detail

Education: Graduated from the Bashkir state medical university majoring in "Medical business". In 2011 gained the diploma and the certificate in Therapy. In 2012 received 2 certificate and the diploma in "Functional diagnosis" and "Cardiology". In 2013 completed courses on "Topical issues of otorhinolaryngology in therapy". In 2014 completed advanced training courses in "A clinical echocardiography" and courses in "Medical rehabilitation".

Experience: From 2011 to 2014 the Policlinic No. 33 Ufa worked as the therapist and the cardiologist in MBUZ. Since 2014 the Policlinic No. 33 Ufa works as the cardiologist and the doctor of functional diagnosis in MBUZ.

PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use Taylenol surely consult with the attending physician.